| Identification | Back Directory | [Name]
1-Piperazinedodecanamide, N-[2-[[2,3-dihydro-2-(1-methyl-2,6-dioxo-3-piperidinyl)-1,3-dioxo-1H-isoindol-4-yl]amino]ethyl]-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-λ-oxo- | [CAS]
2523017-04-9 | [Synonyms]
1-Piperazinedodecanamide, N-[2-[[2,3-dihydro-2-(1-methyl-2,6-dioxo-3-piperidinyl)-1,3-dioxo-1H-isoindol-4-yl]amino]ethyl]-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]-λ-oxo- | [Molecular Formula]
C48H55FN8O8 | [MOL File]
2523017-04-9.mol | [Molecular Weight]
891 |
| Hazard Information | Back Directory | [Description]
SK 575-NEG is the negative control for SK 575. | [Uses]
SK-575-NEG (compound 28), a methylation counterpart of SK-575, is synthesized by methylation of the amino group of piperidine-2,6-dione in SK-575 as an control compound. SK-575-NEG is strongly bound to PARP1, with an IC50 of 2.64 nM. SK-575-NEG was completely ineffective in inducing PARP1 degradation in MDA-MB-436 and Capan-1 cells at concentrations up to 1 μM[1]. | [IC 50]
PARP-1: 2.64 nM (IC50) | [storage]
Store at -20°C | [References]
[1] Cao C, et al. Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers. J Med Chem. 2020 Oct 8;63(19):11012-11033. DOI:10.1021/acs.jmedchem.0c00821 |
|
|